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A B S T R A C T
Purpose: Intravenous (IV) formulations are useful when treating patients where oral administration is
not possible and to study certain pharmacokinetic parameters such as bioavailability. We developed a
stable-labeled IV formulation of lamotrigine (LTG) for studying pharmacokinetics in epilepsy patients.
Methods: Stable-labeled IV LTG was given to 20 persons with epilepsy (6 men; 14 women) with a mean
age of 34.8 years (SD 11.7). A 50 mg dose of LTG (stable labeled) was given intravenously and replaced
50 mg of the regular morning oral dose of LTG (unlabeled, commercially available formulation).
Results: No signiﬁcant changes in blood pressure, heart rate, or adverse events including rash were
attributed to administration of a 50-mg dose of the intravenous LTG formulation.
Conclusion: Our results show that LTG base that is complexed with 2-hydroxypropyl-b-cyclodextrin and
stable-labeled can be given safely as a tracer replacement dose.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Lamotrigine (LTG) is only available commercially as oral
formulations. Intravenous (IV) formulations are useful when
treating patients where oral administration is not possible and
to study certain pharmacokinetic parameters such as bioavailabil-
ity. We developed a formulation of LTG with a 25% 2-hydro-
xylpropyl-b-cylodextrin as the vehicle for the purpose of exploring
steady state elimination. Clinically an intravenous formulation of
LTG could be useful for short term replacement dosing when
patients have an interruption in their oral route of administration
for reasons such as surgery or vomiting. For research purposes,
the incorporation of a stable-label (SL) into the LTG molecule
permitted the analytical differentiation between orally adminis-
tered LTG (unlabeled) from that LTG administered intravenously
(SL) by gas chromatography–mass spectrometry and enabled
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formulation given as a small tracer dose to patients who are
currently receiving LTG for clinical reasons.
2. Methods
2.1. Subjects
This study was performed at the University of Minnesota and
Emory University. The Institutional Review Board Human Subject’s
Committees at all sites approved this study. All patients and/or
guardians provided consent. Adult patients (18–63 years) who
were already on a steady-state dose of LTG were enrolled into the
study. Patients with signiﬁcant cardiovascular disease that might
prevent them from tolerating an intravenous infusion or who were
receiving any medications that might affect LTG pharmacokinetics
were excluded.
2.2. Formulation
This SL-LTG formulation was approved by the FDA for research
purposes (IND # 72,642). [13C2,
15N]-LTG was labeled in three
positions by Cambridge Isotope Laboratories (Andover, MA). The
stable isotope form of LTG was formulated for intravenous
administration in a 25% (w/v) 2-hydroxypropyl-b-cyclodextrinvier Ltd. All rights reserved.
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tics Division at the University of Iowa. The formulation was
dispensed into 5 mL single use ampoules.
2.3. Study design
Subjects were admitted to a research center and were under
medical supervision for a minimum of 8 h. A normal saline infusion
was started at 50 ml/h prior to and maintained for 30 min after the
infusion. A single 50 mg dose of SL-LTG was administered
undiluted IV over 15 min at a rate of 0.33 ml/min with a syringe
pump. After the infusion was complete, each subject took his/her
usual maintenance morning oral LTG dose less 50 mg followed by
the remainder of their daily dose at the normally prescribed time. A
physician assessed each subject via a brief neurological exam
before and after each intravenous SL-LTG administration. The
infusion site was inspected for signs of inﬂammation throughout
the study. Patients were asked during the infusion if they were
experiencing discomfort at the infusion site or any other
symptoms. A 3-lead electrocardiogram (ECG) was obtained prior
to, during, and immediately after the infusion. Blood pressure (BP)
and heart rate (HR) were measured prior to, every 2 min during,
then every 15 min (for the ﬁrst hour) following completion of
the infusion. Early study termination points were an AV block (PR
interval greater than 200 ms), bradycardia less than 50 beats per
minute (unless baseline is less than 50), emergence of any
arrhythmia not present at baseline, or if systolic or diastolic BP
changed by more than 30 mmHg from baseline during the infusion.
The percent change of BP and HR were calculated for two
periods: period 1 (pre-infusion to end of infusion) and period 2 (30-
min post-infusion to end of infusion). Statistical analysis included a
paired t-test comparing the two periods (SPSS Version 20.0). A p
value of <0.05 was considered signiﬁcant.
3. Results
Twenty (6 men/14 women; 1 African American/19 Caucasians)
subjects were enrolled and completed the study. The mean age was
34.8 years (SD = 11.7, range 18–63 years). The mean weight was
72.1 kg (SD = 17.3, range 48.3–117.3 kg). The mean maintenance
LTG dose was 463.8 mg (range 200–800 mg). Complete BP and HR
data were available for 18 subjects. One subject was missing aTable 1
Characteristics of vital signs before and after infusion.
Baseline (predose) End
Systolic blood pressure (mmHg)
N 19 20 
Mean (SD) 117 (12.8) 114
Range 93–139 95–
N 19 
% change from baseline (SD) 1.
Range 11
Diastolic blood pressure (mmHg)
N 19 20 
Mean (SD) 74 (9.2) 70 (
Range 57–93 52–
N 19 
% change from baseline (SD) 3.
Range 31
Heart rate (beats/min)
N 20 19 
Mean (SD) 67 (9.8) 68 (
Range 49–83 47–
N 19 
% change from baseline (SD) 3.3 
Range 11
SD, standard deviation.baseline BP measurement and another subject was missing a HR
measurement at the end of infusion. The infusion was well tolerated
and no infusions were discontinued due to safety concerns.
There were no statistical differences in the percent change from
baseline to end of infusion or from baseline to 30 min post infusion
for systolic or diastolic blood pressure or heart rate. (Table 1). There
were no drug related adverse events. Rash was not observed
although one subject had some redness around the infusion site;
however, it was concluded to be due to irritation from the IV
infusion needle. A second person reported a feeling of chest
tightness. The ECG was normal and the tightness resolved quickly.
This subject had reported nasal congestion and pre-syncopal
symptoms prior to the infusion.
4. Discussion
This is the ﬁrst report on the safety of a cyclodextrin-based
intravenous LTG formulation given to humans. Most AEDs are
approved as oral solid formulations due to their insolubility or lack
of commercial interest in developing an intravenous formulation.
The use of intravenous stable isotope labeled formulations can
aid in pharmacokinetic studies especially when studying medica-
tions used in therapeutic areas such as epilepsy where chronic
therapy cannot be interrupted for clinical and ethical reasons.
For clinical purposes, the availability of intravenous formulations
may be useful as short term replacement therapy. Our group
has developed stable-labeled intravenous formulations of various
AEDs (fosphenytoin, phenytoin, carbamazepine, valproic acid and
topiramate) for studies evaluating the effect of age on pharmaco-
kinetics and absolute bioavailability.1–5 Currently, two of these
products (intravenous carbamazepine and topiramate) are being
investigated for clinical use.
Whereas some AEDs, such as valproic acid have good water
solubility and commercially available parenteral solutions, others
do not. Only one report exists that describes LTG given to eight
healthy volunteers via intravenous administration. Yuen and Peck
reported the pharmacokinetics of LTG after administration of a
water-soluble LTG salt (LTG isethionate) with 4% dextrose infused
over 30 min.6 Both the oral and intravenous formulations used in
this study were reported to have no adverse events or changes
in vital signs; however, no safety data were presented. Inclusion
complexes of water insoluble drugs with cyclodextrins can of infusion 30 min after end of infusion p-Value
20
 (11.3) 114 (12.3)
143 94–136
19
2 (7.2) 1.4 (7.4)
.9 to 14.5 17.0 to 16.2 0.92
20
10.9) 70 (11.2)
86 42–93
19
6 (11.7) 4.8 (13.8)
.0 to 19.7 30.1 to 16.4 0.68
20
11.7) 69 (11.2)
93 47–86
19
(8.7) 3.0 (8.7)
.0 to 29.2 15.8 to 19.4 0.90
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an oral solution or intravenous formulation.7 Previous reports with
LTG cyclodextrin complexes explored the feasibility of cyclodex-
trin as an excipient to improve pharmacokinetic characteristics in
solid dosage formulations,8,9 but not possible intravenous for-
mulations. Remmel and Sinz previously evaluated the pharmaco-
kinetics and metabolism of IV LTG in guinea pigs with a
hydroxypropyl-b-cyclodextrin formulation.10 A possible limita-
tion of this formulation is the risk of rash or more severe allergic
reactions such as Stevens–Johnson syndrome. The risk of rash from
LTG increases with higher doses and faster titration rates.11 Due to
a higher bioavailability of an intravenous over an oral formulation
it is possible that patients who are already receiving LTG orally
may be at higher risk of rash due to higher concentrations of drug
delivered directly to the circulatory system via the intravenous
route. The absolute bioavailability of a single 75 mg dose of the
water-soluble intravenous formulation was 98  0.05% indicating
that there may be little difference in drug concentrations compared to
the oral formulation.6 There were no signs of rash in our study in
patients on a 50 mg LTG steady state dose. Studies at higher
intravenous doses are needed to assess the clinical utility of the
formulation and the risk of adverse events.
To the best of our knowledge, this is the ﬁrst report of LTG
complexed with 2-hydroxypropyl-b-cyclodextrin intravenously
being administered to patients. Our results show that LTG base that
is complexed with 2-hydroxypropyl-b-cyclodextrin and stable-
labeled can be given safely as a tracer replacement dose. These
results are similar to those observed with a study dose of stable-
label-cyclodextrin complexed carbamazepine.12 A limitation of
this report is the relatively small sample size. Additional studies
with larger doses are needed in order to determine the utility of
this formulation as a full dose replacement for bridge therapy
when delivering medications orally is not possible.
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